Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch
GeekWire
JULY 7, 2021
Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. Biotech IPOs reached an all-time high last year, according to Biopharma Dive , and the pace is continuing into 2021. Net losses were $5.3 Icosavax Photo). million in 2019 and $18.9
Let's personalize your content